Company Overview of MPM Capital

Snapshot

People

Overview Board Members Committees

Executive Profile

Ansbert K. Gadicke M.D., Ph.D.

Co-Founder, Managing Director, and General Partner, MPM Capital

Age	Total Calculated Compensation	This person is connected to 5 Board Members in 5 different organizations across 17 different industries. See Board Relationships
54	--

Background

Dr. Ansbert K. Gadicke, M.D., Ph.D. is a Co-Founder, Managing Director, and General Partner at MPM Capital. Dr. Gadicke is the Founder of the MPM Group and co-founded its asset management business in 1996. He led its effort to build its advisory and investment banking business from 1992 to 1996. Previously, he was employed at Boston Consulting Group from 1989 to 1992, where Dr. Gadicke worked with management of pharmaceutical, biotechnology, and health insurance companies. ... He has held research positions in biochemistry and molecular biology at the Whitehead Institute at Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. At the German Cancer Research Center, he cloned the first cDNAs of HPV16 and 18 in Prof. Harald zur Hausen's group (Nobel Laureate in Physiology or Medicine, 2008). Dr. Gadicke served as the Chairman of Elixir Pharmaceuticals. Dr. Gadicke serves as a Director at Centagenetix, Mindset Biopharmaceuticals, Dragonfly Sciences, Inc., JapanBridge Pharmaceuticals, and Nuvios. He has been Director of Radius Health, Inc. since May 2011 and Sideris Pharmaceuticals, Inc. He served as a Vice Chairman of Idenix Pharmaceuticals Inc. until May 2005. He served as Director of Solasia Pharma K.K. He served as a Director of DoubleTwist Inc. since February 2000. Dr. Gadicke served as a Director of LXN Corporation since April 1999 and Endeavor Pharmaceuticals Inc. since 2000. He served as Non Executive Director of Verastem, Inc. from November 2010 to November 26, 2012. He served as Director of Elixir Pharmaceuticals, Inc. since February 2003. He served as a Director at Cerimon Pharmaceuticals, Inc., Novirio Pharmaceuticals, Ltd., Arriva Pharmaceuticals, Inc, BioMarin Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, Omrix Biopharmaceuticals, Inc., Coelacanth Chemical Corporation, MediGene AG, Transform Pharmaceuticals, Chiasma (Israel) Ltd., Kourion Therapeutics GmbH and PharmAthene, Inc. He served as a Director of Pharmasset, Inc. from June 1999 to October 15, 2007. Dr. Gadicke served as a Director of Idenix Pharmaceuticals Inc. from 1998 to May 2005. He served as a Director of Xanodyne Pharmaceuticals, Inc. since July 2007 and ViaCell, since January 1998. Dr. Gadicke serves as the Co-Chairman of the Alumni Association of the Whitehead Institute. He is a Member of the Advisory Councils for Harvard Medical School, the Human Science and Technology Program of Harvard University and M.I.T., as well as the Whitehead Institute at M.I.T. Dr. Gadicke is a Member of Board of Fellows of Harvard Medical School and the MGH Research Advisory Council. Dr. Gadicke has served on the Board of the National Venture Capital Association. Dr. Gadicke has published in leading scientific publications including Nature and Cell. He holds an M.D. from the J.W. Goethe University in Frankfurt.

Read Full Background